Pediatric Prozac clears FDA
FDA clears Lilly's Prozac (fluoxetine) for treatment of major depressive disorder and obsessive compulsive disorder in children seven to 17 Jan. 3. The company received additional market exclusivity from February 2001 until August 2001 for conducting the pediatric trials. As a Phase IV postmarketing commitment, Lilly will "evaluate any potential impact of fluoxetine on long-term growth in children," an FDA 1talk paper says...
You may also be interested in...
Lilly's Phase IV commitments for additional research on pediatric use of Prozac will serve as a high-profile test of FDA's pediatric exclusivity incentive
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Executive order calls for short-term and long-term study, broad consultation, coordination with allies.